Previous close | 1.0770 |
Open | 1.1850 |
Bid | 1.1575 x N/A |
Ask | 1.2035 x N/A |
Day's range | 1.1850 - 1.1860 |
52-week range | 1.0135 - 2.4570 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
PLX Sees Regulatory Approvals and Commercial Progress Amidst Financial Growth